Sarepta Therapeutics (SRPT) Short term Debt (2010 - 2025)

Sarepta Therapeutics' Short term Debt history runs 12 years deep, the most recent figure standing at $36.0 million for Q3 2025.

• In Q3 2025, Short term Debt fell 60.7% year-over-year to $36.0 million; the TTM figure through Sep 2025 stood at $36.0 million (down 60.7% YoY), while the FY2023 annual figure was $105.5 million, changed N/A from the prior year.
• Short term Debt was $36.0 million for Q3 2025 at Sarepta Therapeutics, down from $91.6 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $105.6 million in Q1 2024 to a low of $36.0 million in Q3 2025.
• Historically, Short term Debt has averaged $86.0 million across 3 years, with a median of $91.6 million in 2024.
• Biggest YoY gain for Short term Debt was 60.7% in 2025; the steepest drop was 60.7% in 2025.
• A 3-year view of Short term Debt shows it stood at $105.5 million in 2023, then fell by 13.17% to $91.6 million in 2024, then plunged by 60.7% to $36.0 million in 2025.
• The last three Short term Debt figures came in at $36.0 million (Q3 2025), $91.6 million (Q3 2024), and $91.5 million (Q2 2024), per Business Quant data.